Onglyza Associated with Pancreatitis, Pancreatic Cancer, and Cardiac Issues
The Type 2 diabetes medication, Onglyza (saxagliptin), is often offered as a preferred option for diabetics, along with a healthy lifestyle, including exercise and diet; however, Onglyza has been associated with increased risks for pancreatic cancer and heart issues. Approved in 2009, Onglyza was released as a collaboration … [Read more...] about Onglyza Associated with Pancreatitis, Pancreatic Cancer, and Cardiac Issues
FDA Issues Another Warning for Type 2 Diabetes Drug
Late last month, the U.S. Food and Drug Administration (FDA) warned that diabetes medications such as sitagliptin, saxagliptin, linagliptin and alogliptin could lead to “severe and disabling” joint pain. The agency said in a safety announcement that this risk would be added to the labels of all medicined in the dipeptidyl peptidase-4 … [Read more...] about FDA Issues Another Warning for Type 2 Diabetes Drug
